Prelude Therapeutics Incorporated (PRLD) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 4.58M | 5.64M | 6.5M | 0 | 0 | 4M | 3M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | 41% | 116.67% | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 391K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 331K | 0 | 0 |
| COGS % of Revenue | 8.54% | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 4.19M | 5.64M | 6.5M | 0 | 0 | 4M | 3M | 0 | 0 | -331K | 0 | 0 |
| Gross Margin % | 91.46% | 100% | 100% | - | - | 100% | 100% | - | - | - | - | - |
| Gross Profit Growth % | - | 41% | 116.67% | - | - | 1308.46% | - | - | - | - | - | - |
| Operating Expenses | 18.37M | 22.99M | 26.92M | 32.19M | 34.61M | 37.83M | 37.38M | 37.16M | 34.34M | 37.05M | 33.38M | 32.4M |
| OpEx % of Revenue | 401% | 407.59% | 414.12% | - | - | 945.78% | 1245.87% | - | - | - | - | - |
| Selling, General & Admin | 4.76M | 5M | 5.21M | 6.41M | 5.79M | 6.21M | 7.92M | 7.66M | 6.93M | 6.72M | 7.12M | 7.43M |
| SG&A % of Revenue | 104.04% | 88.58% | 80.15% | - | - | 155.28% | 263.97% | - | - | - | - | - |
| Research & Development | 13.6M | 17.99M | 21.71M | 25.78M | 28.82M | 31.62M | 29.46M | 29.51M | 27.41M | 30.33M | 26.26M | 24.97M |
| R&D % of Revenue | 296.97% | 319.01% | 333.97% | - | - | 790.5% | 981.9% | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
| Operating Income | -14.18M | -17.35M | -20.42M | -32.19M | -34.61M | -33.83M | -34.38M | -37.16M | -34.34M | -37.38M | -33.38M | -32.4M |
| Operating Margin % | -309.54% | -307.59% | -314.12% | - | - | -845.78% | -1145.87% | - | - | - | - | - |
| Operating Income Growth % | 59.03% | 48.72% | 40.6% | 13.37% | -0.77% | 9.49% | -2.97% | -14.71% | -17.96% | -11.96% | -9.8% | -9.97% |
| EBITDA | -13.79M | -16.93M | -19.99M | -31.76M | -34.17M | -33.34M | -33.97M | -36.71M | -33.92M | -37.05M | -33.11M | -32.12M |
| EBITDA Margin % | -301% | -300.18% | -307.58% | - | - | -833.55% | -1132.37% | - | - | - | - | - |
| EBITDA Growth % | 59.66% | 49.22% | 41.15% | 13.49% | -0.75% | 10% | -2.61% | -14.31% | -17.62% | -12.19% | -10.1% | -10.2% |
| D&A (Non-Cash Add-back) | 391K | 418K | 425K | 433K | 435K | 489K | 405K | 452K | 426K | 331K | 279K | 281K |
| EBIT | -14.18M | -17.35M | -20.42M | -32.19M | -34.61M | -33.83M | -34.38M | -37.16M | -34.34M | -33.08M | -33.38M | -32.4M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3.79M | 891K | 693K | 963K | 2.52M | 5.1M | 2.1M | 2.42M | 2.91M | 4.3M | 2.78M | 1.97M |
| Pretax Income | -10.38M | -16.46M | -19.73M | -31.23M | -32.09M | -28.73M | -32.27M | -34.74M | -31.43M | -33.08M | -30.61M | -30.43M |
| Pretax Margin % | -226.75% | -291.79% | -303.46% | - | - | -718.28% | -1075.7% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -10.38M | -16.46M | -19.73M | -31.23M | -32.09M | -28.73M | -32.27M | -34.74M | -31.43M | -33.08M | -30.61M | -30.43M |
| Net Margin % | -226.75% | -291.79% | -303.46% | - | - | -718.28% | -1075.7% | - | - | - | - | - |
| Net Income Growth % | 67.63% | 42.72% | 38.88% | 10.1% | -2.08% | 13.13% | -5.43% | -14.16% | -13.4% | -15.48% | -2.17% | -11.17% |
| Net Income (Continuing) | -10.38M | -16.46M | -19.73M | -31.23M | -32.09M | -28.73M | -32.27M | -34.74M | -31.43M | -33.08M | -30.61M | -30.43M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.13 | -0.26 | -0.26 | -0.41 | -0.42 | -0.38 | -0.43 | -0.46 | -0.42 | -0.48 | -0.45 | -0.54 |
| EPS Growth % | 69.05% | 31.58% | 39.53% | 10.87% | 0% | 20.83% | 4.44% | 14.81% | 23.64% | -9.09% | 27.42% | -1.89% |
| EPS (Basic) | -0.13 | -0.26 | -0.26 | -0.41 | -0.42 | -0.38 | -0.43 | -0.46 | -0.42 | -0.48 | -0.45 | -0.54 |
| Diluted Shares Outstanding | 82.52M | 62.95M | 76.13M | 75.99M | 75.99M | 75.9M | 75.86M | 75.76M | 75.74M | 69.59M | 67.64M | 56.24M |
| Basic Shares Outstanding | 82.52M | 62.95M | 76.13M | 75.99M | 75.99M | 75.9M | 75.86M | 75.76M | 75.74M | 69.59M | 67.64M | 56.24M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |